Bionomics Limited (BNO.AX)
| Previous close | 0.2600 |
| Open | 0.2600 |
| Bid | 0.2750 x 0 |
| Ask | 0.2850 x 0 |
| Day's range | 0.2600 - 0.3100 |
| 52-week range | 0.0283 - 0.4850 |
| Volume | 931,924 |
| Avg. volume | 1,637,214 |
| Market cap | 240.977M |
| Beta (5Y monthly) | 2.79 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0010 |
| Earnings date | 16 Aug 2016 - 20 Aug 2016 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 0.63 |
- PR Newswire
Positive BNC210 7-Day Dosing Pharmacokinetic Study Exceeds Blood Exposure Projected for Phase 2b PTSD Trial
Bionomics Limited (ASX: BNO, OTCQB: BNOEF, Germany: AU000000BNO5), a global, clinical stage biopharmaceutical company, today announced positive pharmacokinetic (PK) results from a 7-day dosing study in healthy volunteers using the newly developed solid dose oral tablet formulation of BNC210. BNC210 is a novel, negative allosteric modulator of the alpha 7 nicotinic acetylcholine receptor in development for the treatment of anxiety and stressor-related disorders, and in November 2019 was granted Fast Track designation by the US Food and Drug Administration (FDA) for the treatment of Post-Traumatic Stress Disorder (PTSD).
- PR Newswire
Joint feasibility assessment of Bionomics' BNC210 and EmpathBio's MDMA derivative EMP-01 treatment regimen for PTSD
Bionomics Limited (ASX: BNO, OTCQB: BNOEF, Germany: AU000000BNO5) (Bionomics) today announced that it has entered into a Memorandum of Understanding with EmpathBio Inc (EmpathBio), a wholly owned subsidiary of Germany-based CNS clinical development company, atai Life Sciences (atai). Under the Memorandum of Understanding, Bionomics and EmpathBio propose to collectively explore a combination drug treatment regimen with Bionomics' BNC210 and EmpathBio's 3,4-Methylenedioxymethamphetamine (MDMA) derivative EMP-01. The parties will explore whether the different mechanisms of action of EMP-01 and BNC210 may offer the potential for developing an improved treatment regimen for the treatment of Post-Traumatic Stress Disorder (PTSD).
- PR Newswire
$16 Million Capital Raise to Progress Bionomics BNC210 PTSD Trial
Bionomics Limited (ASX: BNO, OTCQB: BNOEF, Germany: AU000000BNO5), a global, clinical stage biopharmaceutical company, is pleased to announce that it has entered into placement agreements with a number of North American and European institutional and sophisticated investors, to raise A$15,991,634. The Company used its 15% placement capacity under Listing Rule 7.1 of 110,287,132 shares.
